Orthopedic Hyaluronic Acid Market Analysis | Canada | 2016-2022 | MedCore

  • Year: 2016
  • Scope: 2012-2022
  • Region: Canada
  • Pages: 40
  • Published Date: 11/1/2016
  • Type: MedCore

Product Description

Hyaluronic acid viscosupplementation (HA) as a treatment for osteoarthritis has been available in Canada since the late 90’s with the major international brands receiving regulatory approval from Health Canada in 1999 and 2000. Unlike many other HA markets around the world, Canada has never seen the five-injection market reaching scale, instead the three-injection market served as the first mainstream product for the HA treatment until 2003 when the first single-injection product became available. The three-injection market slowed and subsequently started to decline when other established brands also started marketing single-injection solutions in 2009. As of 2015 the market split between single and three-injection products continues to trend towards single-injection, albeit at a slower pace; single-injection market is currently occupying 57.5% of the total market with the three-injection market accounting for the balance, slightly up from 2012 when single-injection market accounted for 55% share. No device was strictly indicated as a five-injection course only; two brands (Hyalgan® and Ostenil®) are sold as individually packaged syringes and an immaterial number of their units were found to be used as five-injection solutions. For the purpose of this report, all estimated units for these two brands were accounted for under the three-injection category.

FREE Sample Report

The "Canadian Market Report for Orthopedic Biomaterials 2016 - MedSuite" includes analysis on the following companies currently active in this market:
Wright Medical
Canadian Local Tissue Banks
RTI Surgical
Zimmer Biomet
Anika Therapeutics
Ferring Pharma
Aralez Pharma
IGEA Medical
Fintek Bio-Electric
BTT Melmak
ITO Company
Others include: Aptissen SA, Fidia Pharma, Mylan Institutional and TRB Chemedica.
Others include: Baxter, Davol, LifeNet Health, MTF, Novabone, OrthoVita, Smith & Nephew, etc.
*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Explore Options

Report Summary


Select License Type

One of the market limiters for the Canadian HA market is the reimbursement structure. None of the products are covered under standard healthcare plans and must be purchased directly or through extended healthcare coverage or private insurance. Thus, some patients opt out to receiving cortisone injections; these are reimbursed by standard healthcare and are a more affordable choice.
One of the factors that contributed positively to this market is ever expanding indication. The market originally started with treating osteoarthritis (OA) of the knee, since then some products expanded into hip, shoulder, a number of small joints, as well as assisting with post-surgery joint recovery.

  • 2016
  • 2012-2022
  • Canada
  • 11/1/2016
  • 40
  • MedCore
    Your Cart
    Your cart is emptyReturn to Report Library